We served as lead counsel representing a national pharmaceutical ingredient supplier and its wholly-owned subsidiaries in an investigation of alleged False Claims Act (FCA) violations concerning inflated Average Wholesale Prices, kickbacks to physicians, and waivers of co-pays.  After a several-year investigation based on the filing of four separate qui tams, we negotiated a successful resolution of the litigation that was far less than the government’s alleged damages of several hundred million dollars. Reported decision: U.S. ex rel. Hueseman v. PSI et al., (WDTX) and U.S. ex rel. Sten v. Midwest Compounders, et al., (NDIA).